Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast Eli Lilly’s profit ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound ... Lilly Institute for Genetic Medicine in Boston, away from Lilly's headquarters in Indianapolis and in one of the U.S. epicenters for this work.

Eli Lilly & Co. is tapping the U.S. investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...